期刊文献+

补充硒减轻5-氟尿嘧啶对大鼠的脂质过氧化损害 被引量:1

Supplymentation of selenium reduces lipoperxidative damage by 5 fluorouracil in rats
下载PDF
导出
摘要 目的:探讨补充硒以减轻5-氟尿嘧啶(5-FU)对大鼠脂质过氧化损害的机制。方法:60只大鼠随机分为补硒组(Se)和非补硒组(NSe),经腹腔注射5-FU后,分别于注射前及注射后第1、3、5天处死,检测大鼠血液、心、肝、肾及空肠粘膜内丙二醛含量及谷胱甘肽过氧化物酶活性。结果:在Se组,血中及空肠粘膜内丙二醛含量在注射5-FU后第1、3天,心、肝、肾组织内丙二醛含量在注射5-FU后第3天显著低于NSe组;红细胞谷胱甘肽过氧化物酶活性在注射5-FU后一直显著高于NSe组(P<0.01),空肠粘膜在注射5-FU后第1天,心、肝、肾组织内在注射5-FU后第3天,谷胱甘肽过氧化物酶活性显著高于NSe组(P<0.05)。结论:补充硒有助于减轻5-FU对大鼠的脂质过氧化损害。 Objective:To evaluate the mechanisms of supplymentation of selenium(Se) reducing lipoperoxidative damage by 5 fluorouracil(5 FU) in rats. Methods:Sixty Sprague dawely rats were randomly divided into Se group and NSe group.After received intraperitoneal injection of 5 FU,they were sacrificed before( n =6) and on day 1,3 and 5( n =8) after injection respectively for the measurement of malondialdehyde(MDA) content,glutathione peroxidase(GGSH Px) activity in blood,heart,kidney,liver and jejunal mucosa. Results:MDA content in blood,heart,kidney,liver and jejunal mucosa was significantly lower in the Se group than in the NSe group on day 3,whereas it was also significantly lower in the Se group than in the NSe group in blood and jejunal mucosa on day 1 after injection.Erythrocyte GSH Px activity was significantly higher in the Se group than in the NSe group at different times.GSH Px activity in jejunal mucosa on day 1,and in heart,liver and kidney on day 3 was significantly higher in the Se group than in the NSe group after injeciton. Conclusion:Supplymentation of Se may reduce lipoperoxidative damage by 5 FU in rats.
出处 《肠外与肠内营养》 CAS 1998年第1期18-20,共3页 Parenteral & Enteral Nutrition
关键词 5-氟尿嘧啶 肿瘤 药物疗法 脂质过氧化 Selenium 5 fluorouracil Malondialdehyde Glutathione peroxidase
  • 相关文献

同被引文献19

  • 1李和平,阮建明,蔡红革,潘彤.壳聚糖-5-氟尿嘧啶高分子前药的合成与表征[J].长沙理工大学学报(自然科学版),2005,2(4):84-88. 被引量:15
  • 2李和平,肖华伍,龙姝,肖子丹,阮建明.壳聚糖-5-氟尿嘧啶微球的制备[J].长沙理工大学学报(自然科学版),2006,3(4):91-96. 被引量:6
  • 3王华丽,张劲松,俞汉青.低毒性的纳米硒对顺铂抗肿瘤作用的影响[J].营养学报,2007,29(5):445-447. 被引量:7
  • 4Michoda D., Widmann C., Crit. Rev. Oncol. Hemat., 2007, 63(2), 160—171.
  • 5Kimura M., Rabbani Z., Mouraviev V., Tsivian M., Caso J., Satoh T., Baba S., Vujaskovic Z., Baust J. M., Baust J. G., Polascik T. J., Urology, 2010, 76(3), 764.e14—764.e20.
  • 6Djazayeria K., Szilvássya Z., Benk?b K., Rózsaa B., Szabóa B., Szentmiklósia A. J., Benk? I., Pharmacol. Res., 2006, 53(2), 156—161.
  • 7Zhang J., Peng D., Lu H., Liu Q., Toxicol. Appl. Pharm., 2008, 226(3), 251—259.
  • 8Ji J. G., Zhang J. F., Hao S. L., Wu D. J., Liu L., Xu Y., Chem. Res. Chinese Universites, 2012, 28(1), 166—170.
  • 9Tong C. Y., Liu B., Li F., Zhang Z. M., Liao H. D., Liu X. M., J. Control Release, 2013, 172(1), e24.
  • 10Rajan M., Raj V., Al-Arfaj Abdullah A., Murugan A. M., Int. J. Pharm., 2013, 453(2), 514—522.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部